Xeljanz Tablet, Film Coated
Product Images NDC 0069-1002

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Xeljanz (NDC 0069-1002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Xeljanz 01)

FDA Label Image

Figure 1 (Xeljanz 02)

FDA Label Image

Figure 2 (Xeljanz 03)

This text appears to be a chart or a table with information about the drug Methotrexate and its effects on other substances such as Midazolam, Levonorgestrel, Ethinyl Estradiol, and Metformin. It also shows recommendations for dose adjustments and ratios relative to a reference. The text is not very informative on its own and seems to be missing some important context. The unclear characters make it difficult to provide a detailed analysis of the text.*

FDA Label Image

Figure 3 (Xeljanz 04)

FDA Label Image

Figure 4 (Xeljanz 05)

This appears to be a graph or chart showing response rates to a medication called XELJANZ at 5mg twice daily compared to a placebo. The response rates are measured at different time intervals (0, 1, and 3 months). The chart also mentions the use of non-responder imputation for patients who withdrew from the study or did not see at least a 20% improvement in joint counts at Month 3. Further context or information is not available.*

FDA Label Image

Figure 5 (Xeljanz 06)

This appears to be a table with two columns and two rows. The first column header is "Visit (Month)" and the second column header is "Response Rate (SE) (%)." The data in the table is related to the comparison of the drug Tofacitinib at a dosage of 5 mg twice daily versus a placebo. However, without additional context or data, the description is limited.*

FDA Label Image

Xeljanz 06a

FDA Label Image

Figure 6 (Xeljanz 07)

FDA Label Image

Figure 7 (Xeljanz 08)

This text indicates that Pfizer Labs, a division of Pfizer Inc based in New York City, NY 10017, is the distributor.*

FDA Label Image

Xeljanz 09

This text is a brief description about the distributor of a product. It mentions that the product is distributed by Pfizer Labs, which is a division of Pfizer Inc. The location of the division is also given as NY, NY 10017.*

FDA Label Image

Logo (Xeljanz 10)

This appears to be a product package for XELJANZ oral solution, which includes a press-in bottle adapter, an oral dosing syringe, and a bottle of the solution itself. The package includes a diagram showing the components of the oral dosing syringe and the press-in bottle adapter. The syringe is likely used to help measure out doses of the oral solution, which is contained in the bottle.*

FDA Label Image

Logo (Xeljanz 11)

This text provides a simple instruction on how to handle a bottle that is packaged in a carton.*

FDA Label Image

Image (Xeljanz 12)

FDA Label Image

Step 1 (Xeljanz 13)

FDA Label Image

Step 2 (Xeljanz 14)

FDA Label Image

Step 3 (Xeljanz 15)

FDA Label Image

Step 4 (Xeljanz 16)

FDA Label Image

Step 5 (Xeljanz 17)

FDA Label Image

Step 6 (Xeljanz 18)

FDA Label Image

Step 7 (Xeljanz 19)

FDA Label Image

Step 8 (Xeljanz 20)

FDA Label Image

Step 9 (Xeljanz 21)

FDA Label Image

Step 10 (Xeljanz 22)

This is a text indicating that Pfizer Inc's Laboratory Division is the distributor. No further information is provided.*

FDA Label Image

Step 11 (Xeljanz 23)

This text is for the storage, dosage, and use of Xeljanz (tofacitinib) tablets, containing 5mg of tofacitinib citrate. The tablets should be stored between 15°C and 30°C (between 59°F and 86°F), and not be repackaged. Dispensing with medication guide is always recommended. The prescribing information should be consulted before use. Distributed by Pfizer Labs, the tablets come in a bottle of 60 and are manufactured in Ireland. Lot number and other unrecognizable characters are present.*

FDA Label Image

Logo (Xeljanz 24)

Store Xeljanz XR (tofacitinib) tablets at room temperature between 20°C to 25°C (68°F to 77°F). This medication guide contains important information for the safe and effective use of this USP Controlled medication. The package includes 30 extended-release tablets of tofacitinib, manufactured in Ireland by Pfizer Labs Division. Each tablet contains 11 mg of tofacitinib citrate. Rx only.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

This is a medication guide for Xeljanz tablets, distributed by Pfizer Labs, for the treatment of rheumatoid arthritis. It provides information on the dosage, administration, and precautions associated with the medication. The tablets come in packages of 60 and are only available with a prescription. The drug is manufactured in Ireland.*

FDA Label Image

Principal Display Panel (11 mg Tablet Bottle Label)

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

This is a medication guide for oral solution Tofacitinib. The solution should be stored in its original bottle and carton and must be protected from light. Its recommended dosage is mentioned in the instructions for use. The contents of the bottle should be used within 60 days of opening, and the remaining solution should be discarded after that. The medication is distributed by Pfizer Labs and it is Rx only.*

FDA Label Image

Principal Display Panel (22 mg Tablet Bottle Label)

This appears to be the information found on a medication bottle for Xeljanz® (tofacitinib) oral solution. The bottle contains 240 mL of the medication, with a concentration of 1 mg/mL. The oral dosing syringe and adapter are not made with natural rubber latex. There are instructions included for use of the medication, including dosages and use of the syringe. It is important to dispense the medication with the medication guide included. The medication should be stored between 20° C and 25°C (68°F to 77°F), with no excursions permitted between 15°C and 30°C (50°F and 86°F). The medication should be stored in the original bottle and carton to protect it from light, and should be discarded if the tamper-evident seal is broken or missing.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.